The VALOR-CKD trial is a research study that is evaluating the efficacy and safety of the investigational drug veverimer (also known as TRC101) in delaying the progression of chronic kidney disease (CKD) in patients with metabolic acidosis and CKD.
This is an outcomes trial that is enrolling patients worldwide. The primary endpoint of the study is progression of CKD, defined by time to first occurrence of any event in the composite endpoint consisting of a confirmed ≥ 40% reduction in estimated glomerular filtration rate (eGFR), end-stage renal disease (ESRD), and renal death.
The VALOR-CKD trial is being conducted by Tricida, Inc. It is also known as the TRCA-303 trial and can be found on ClinicalTrials.gov under the identifier number NCT03710291.
It is estimated that about 3 million patients with CKD have metabolic acidosis. Metabolic acidosis is caused by the inability of the kidneys to excrete acid, and if left untreated, increases the risk of kidney failure and can lead to muscle protein catabolism, muscle loss, and bone demineralization.1, 2, 3 At this time, there are no FDA-approved treatments for chronic metabolic acidosis. 
Thank you for your interest in the VALOR-CKD trial. If you would like to learn more, or if you have a patient that you would like to refer to the trial, please complete the form below and our clinical trial management team will contact you shortly.
* Required Field
